Early trial tests drug for debilitating nerve damage in rare heart condition
NCT ID NCT05023889
Summary
This small, early-phase study is testing whether the drug patisiran can help control nerve damage in people with wild-type ATTR amyloidosis, a rare condition where abnormal proteins build up in the body. Ten participants with nerve symptoms will receive patisiran infusions every three weeks for two years. Researchers will measure changes in nerve function, symptoms like dizziness and digestive issues, and overall quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Neuromuscler Center/National Neuromuscular Research Institute
Austin, Texas, 78759, United States
Conditions
Explore the condition pages connected to this study.